 DELRAY BEACH, Fla., March 31, 2021 GLOBE NEWSWIRE -- AzurRx BioPharma, Inc. NASDAQ: AZRX, AzurRx or the Company, a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal GI diseases, today provided key takeaways from its conference call reporting on the topline results from its Phase 2b OPTION 2 clinical trial investigating MS1819 in cystic fibrosis CF patients with exocrine pancreatic insufficiency EPI. The conference call, held on March 31, 2021, at 4:30 p.m. ET, featured James Sapirstein, President, CEO and Chairman of AzurRx, and Dr. James Pennington, Chief Medical Officer, discussing the recently completed OPTION 2 study, and the companys plans to develop an optimized formulation of MS1819 for ongoing clinical investigation. 